COVID‐19 with dermatologic manifestations and implications: An unfolding conundrum

Al-Mutairi, Nawaf; Schwartz, Robert A.

doi:10.1111/dth.13544

Cited by 41 publications

(93 citation statements)

References 56 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 Morbilliform rash, pernio-like acral lesions, livedo-like/ retiform purpura/necrotic vascular lesions, urticaria, and vesicular (varicella-like) eruptions were reported as the cutaneous manifestations of COVID-19 in the literature. [12][13][14]20,21 and imaging findings of atypical, severe Kawasaki disease. 22 None of the mentioned lesions were observed in the present study.…”

Section: Discussionmentioning

confidence: 99%

Changing trends in dermatology practice during COVID ‐19 pandemic: A single tertiary center experience

Tanacan

Saraç

Emeksiz

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

Objective To evaluate the changing trends in dermatology clinical practice at a tertiary center during the coronavirus disease 2019 (COVID‐19) pandemic. Method This retrospective cohort study was conducted on patients who were admitted to Ufuk University Hospital with dermatologic complaints/diseases before and during the pandemic. The patients were divided into two groups: 1) the Pre‐pandemic period (March‐May 2019) and 2) the Pandemic period (March‐May 2020). Demographic features, clinical characteristics, dermatologic diseases/complaints, dermatologic procedures/interventions, hospitalization rate, and use of biologic agents were compared between the two groups. Results Total number of hospital admissions have decreased from 1165 to 717. Admission rates for acne, dermatophytosis, and benign neoplasm of the skin significantly lower during the pandemic period (p values were 0.02, 0.04, and 0.006, respectively). Contact dermatitis, acne accompanying dermatitis, cicatricial hair loss, lichen planus, and zona zoster infection rates were significantly higher (p values were 0.007, <0.001, 0.009, 0.04 and 0.03, respectively). Rates of biopsy and electrocautery procedures were decreased significantly (p values were <0.001 and 0.002, respectively). The hospitalization rate was similar between the groups (p=0.51). However, the use of biologic agents significantly decreased during the pandemic period (p=0.01). Conclusion Updated clinical protocols should be established for the new normal period in accordance with these findings. This article is protected by copyright. All rights reserved.

show abstract

Section: Discussionmentioning

confidence: 99%

Changing trends in dermatology practice during COVID ‐19 pandemic: A single tertiary center experience

Tanacan

Saraç

Emeksiz

et al. 2020

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…A number of therapeutic agents are being explored globally against the COVID‐19 infection. Efforts to stop this pandemic should involve many approaches, 13,14 including drug therapy and the use of air cleansing devices 15 . There are encouraging anecdotal results of favorable clinical experiences using azithromycin alone early in the course of a COVID‐19 infection.…”

Section: Discussionmentioning

confidence: 99%

Azithromycin and COVID‐19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration

Schwartz

Suskind

2020

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

The devastating effects of the coronavirus designated severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) have led to urgent attempts to find effective therapeutic agents for inpatient and outpatient treatment of COVID‐19. Initial enthusiasm for the combination of hydroxychloroquine and azithromycin has abated. However, as a result of positive clinical experience with azithromycin used alone during the first few days of the flu‐like illness caused by this coronavirus, we recommend formal clinical trials using azithromycin early in the course of a COVID‐19 infection. There is one clinical trial initiated, the individually randomized, telemedicine‐based, “Azithromycin for COVID‐19 Treatment in Outpatients Nationwide” based at the University of California San Francisco. This placebo‐controlled trial is designed to determine the efficacy of a single 1.2‐g dose of oral azithromycin to prevent COVID‐19 patient progression to hospitalization. We recommend formal clinical trials of azithromycin in its prepackaged form at the first sign of COVID‐19 infection in adults and children, using an initial adult dose of 500 mg followed by 250 mg per day for 4 days, a total cumulative dose of 1.5 g, and for children 5 to 18 years of age, 10 mg/kg on the first day followed by 5 mg/kg for 4 days.

show abstract

“…With current existing limited clinical evidence of the majority of drugs proposed against SARS-Cov-2, a number of therapeutic agents are being explored globally against this catastrophic viral pandemic. 32 Reinforcement of a few commonly utilized dermatological drugs with efficacy against this viral infection in mitigating active infection and its sequelae can further add to the novel treatment strategies. Dermatologist all across the world need to be aware of the potential adverse reactions of the known as well as these new drugs in light of their potentially overzealous use.…”

Section: Resultsmentioning

confidence: 99%

Systemic Medications of Dermatological Importance in COVID-19

Schwartz¹,

Sharma²,

Szepietowski³

et al. 2020

JDD

View full text Add to dashboard Cite

Early December 2019 witnessed an international outbreak of a novel coronavirus (COVID 19) designated severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2). Since then, a number of therapeutic molecules have been explored to have potential efficacy against the SARS-Cov-2 per se or its sequelae. There are no Food and Drug Administration specific therapies approved so far; however, numerous drugs based on varying levels of evidence, in vitro studies and compassionate drug trials are being established as therapeutic agents, especially drugs approved for previous emergence of the severe acute respiratory syndrome (SARS-CoV-1) and Middle east respiratory syndrome coronavirus (MERS-Cov). Numerous active clinical trials for COVID-19 with more than 150 drugs and products are under study. Needless to say, many dermatological drugs are being employed to mitigate this pandemic threat. We aim to review drugs with potential against SARS-Cov-2 widely used in dermatology practice. Additionally, rampant and overzealous use of these drugs as well as introduction of new molecules might lead to emergence of adverse effects associated with these agents. Dermatologists must be on lookout for any cutaneous adverse effects of these drugs.

show abstract

COVID‐19 with dermatologic manifestations and implications: An unfolding conundrum

Cited by 41 publications

References 56 publications

Changing trends in dermatology practice during COVID ‐19 pandemic: A single tertiary center experience

Changing trends in dermatology practice during COVID ‐19 pandemic: A single tertiary center experience

Azithromycin and COVID‐19: Prompt early use at first signs of this infection in adults and children, an approach worthy of consideration

Systemic Medications of Dermatological Importance in COVID-19

Contact Info

Product

Resources

About